Success Metrics

Active Trials
7(70%)

Phase Distribution

Ph phase_3
3
30%
Ph early_phase_1
1
10%
Ph phase_2
2
20%
Ph phase_1
4
40%

Phase Distribution

5

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
3(30.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

7

trials recruiting

Total Trials

10

all time

Status Distribution
Active(9)
Terminated(1)

Detailed Status

Recruiting5
Not yet recruiting2
Active, not recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
7
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (10.0%)
Phase 14 (40.0%)
Phase 22 (20.0%)
Phase 33 (30.0%)

Trials by Status

not_yet_recruiting220%
withdrawn110%
recruiting550%
active_not_recruiting220%

Recent Activity

7 active trials
Showing 5 of 10
active_not_recruitingphase_1

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

NCT06899061
recruitingphase_1

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

NCT07446855
not_yet_recruitingphase_2

Saruparib in HRDsig+ Solid Tumors

NCT07832630
recruitingphase_3

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803
recruitingearly_phase_1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

NCT04005690
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06899061Phase 1

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

Active Not Recruiting
NCT07446855Phase 1

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Recruiting
NCT07832630Phase 2

Saruparib in HRDsig+ Solid Tumors

Not Yet Recruiting
NCT06952803Phase 3

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Recruiting
NCT04005690Early Phase 1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Recruiting
NCT05797168Phase 1

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Recruiting
NCT06120491Phase 3

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Active Not Recruiting
NCT07711002Phase 3

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Not Yet Recruiting
NCT06769126Phase 2

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Recruiting
NCT07060365Phase 1

A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10